- Home
- PLSE vs TNGX Comparison
PLSE vs TNGX Comparison
Compare PLSE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | TNGX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLSE | TNGX |
|---|---|---|
| Price | $53.80 | $23.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $60.67 | $44.88 |
| AVG Volume (30 Days) | 401.8K | ★ 3.5M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $480.71 | N/A |
| Revenue Next Year | $177.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $12.56 | $7.12 |
| 52 Week High | $58.90 | $34.39 |
Technical Indicators
Market Signals| Indicator | PLSE | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 47.72 |
| Support Level | $49.01 | $20.46 |
| Resistance Level | $55.36 | $25.68 |
| Average True Range (ATR) | 3.43 | 1.78 |
| MACD | 0.37 | 0.35 |
| Stochastic Oscillator | 88.36 | 33.57 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.